<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">asurgery</journal-id><journal-title-group><journal-title xml:lang="ru">Амбулаторная хирургия</journal-title><trans-title-group xml:lang="en"><trans-title>Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2712-8741</issn><issn pub-type="epub">2782-2591</issn><publisher><publisher-name>ООО «ГРУППА РЕМЕДИУМ»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">asurgery-19</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ХИРУРГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>SURGERY</subject></subj-group></article-categories><title-group><article-title>Низкомолекулярный гепарин Цибор® - современный опыт применения в хирургической клинической практике</article-title><trans-title-group xml:lang="en"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кудыкин</surname><given-names>М. Н.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>НижГМА</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2015</year></pub-date><volume>0</volume><issue>3-4</issue><fpage>35</fpage><lpage>41</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кудыкин М.Н., 2015</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="ru">Кудыкин М.Н.</copyright-holder><copyright-holder xml:lang="en">Кудыкин М.Н.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.a-surgeon.ru/jour/article/view/19">https://www.a-surgeon.ru/jour/article/view/19</self-uri><abstract><p>Современную клиническую практику нельзя представить без использования антикоагулянтов, и ведущую роль продолжает играть использование гепаринов. Одно из величайших открытий фармакологии - открытие гепарина, наряду с открытием антибиотиков, определило новый вектор в развитии всей клинической медицины и хирургии. Самые разнообразные свойства гепарина как биологического лекарственного средства природного происхождения изучаются на протяжении столетия, начиная с 1916 г., что способствует пополнению базы данных в отношении его эффектов, но на сегодняшний день наиболее частым показанием для назначения гепарина является профилактика и лечение венозного тромбоза и тромбоэмболических осложнений.</p></abstract><kwd-group xml:lang="ru"><kwd>венозный тромбоз</kwd><kwd>профилактика</kwd><kwd>лечение</kwd><kwd>гепарин</kwd><kwd>бемипарин</kwd><kwd>Цибор®</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Guideline on non-ciinicai and clinical development of similar biological medicinal products containing low molecular weight heparins. London, 19 March 2009. EMEA/CHMP/BMWP/118264/2007.</mixed-citation><mixed-citation xml:lang="en">Guideline on non-ciinicai and clinical development of similar biological medicinal products containing low molecular weight heparins. London, 19 March 2009. EMEA/CHMP/BMWP/118264/2007.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Ассоциация флебологов России, Всероссийское общество хирургов. М.: Медиа Сфера, 2010.</mixed-citation><mixed-citation xml:lang="en">Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Ассоциация флебологов России, Всероссийское общество хирургов. М.: Медиа Сфера, 2010.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Geerts WH, Bergqvist D, Pineo GF et al. Prevention of Venous Thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 381-453.</mixed-citation><mixed-citation xml:lang="en">Geerts WH, Bergqvist D, Pineo GF et al. Prevention of Venous Thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 381-453.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for venous thromboembolic disease: antithrombotic therapy and prevention of thrombosis. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). Chest. 2012. 141. 419-494.</mixed-citation><mixed-citation xml:lang="en">Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for venous thromboembolic disease: antithrombotic therapy and prevention of thrombosis. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). Chest. 2012. 141. 419-494.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Guidelines o the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Eur Heart J. 2008; 29: 2276-2315.</mixed-citation><mixed-citation xml:lang="en">Guidelines o the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Eur Heart J. 2008; 29: 2276-2315.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Falkon L, Saenz-Campos D, Antonijoan R, Martin S, Barbanoj M, Fontcuberta J. Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11). A three way cross-over study in healthy volunteers. Thromb. Res. 1995; 78: 77-86.</mixed-citation><mixed-citation xml:lang="en">Falkon L, Saenz-Campos D, Antonijoan R, Martin S, Barbanoj M, Fontcuberta J. Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11). A three way cross-over study in healthy volunteers. Thromb. Res. 1995; 78: 77-86.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Borrell M, Antonijoan RM, Ortin R et al. Pharmacokinetic profiles of two LMWH: Bemiparin 3,500 IU and Enoxaparin 4,000 IU after subcutaneous administration in healthy volunteers. Thromb. Haemost. 2001; 86: Suppl.: CD3578.</mixed-citation><mixed-citation xml:lang="en">Borrell M, Antonijoan RM, Ortin R et al. Pharmacokinetic profiles of two LMWH: Bemiparin 3,500 IU and Enoxaparin 4,000 IU after subcutaneous administration in healthy volunteers. Thromb. Haemost. 2001; 86: Suppl.: CD3578.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Falkon L, Bayes M, Frontera G, Gari M, Barbanoj M, Fontcu-berta J. Pharmacokinetics and tolerability of a new low molecular mass heparin (RO-11) in healthy volunteers - a dose-finding study within the therapeutical range. Thromb. Haemost. 1997; 77: 133-136.</mixed-citation><mixed-citation xml:lang="en">Falkon L, Bayes M, Frontera G, Gari M, Barbanoj M, Fontcu-berta J. Pharmacokinetics and tolerability of a new low molecular mass heparin (RO-11) in healthy volunteers - a dose-finding study within the therapeutical range. Thromb. Haemost. 1997; 77: 133-136.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Collignon F, Frydman A, Caplain H et al.: Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalte- parin, enoxaparin, nadroparin - administered subcutaneousiy in heathy volunteers (doses for prevention of thromboembolism). Thromb. Haemost. 1995; 73: 630-640.</mixed-citation><mixed-citation xml:lang="en">Collignon F, Frydman A, Caplain H et al.: Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalte- parin, enoxaparin, nadroparin - administered subcutaneousiy in heathy volunteers (doses for prevention of thromboembolism). Thromb. Haemost. 1995; 73: 630-640.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Eriksson BI, Soderberg K, Widiund L, Wandeii B, Tengborn L. A comparative study of three iow-moiecuiar weight heparins (LMWH) and unfractionated heparin (UH) in healthy voiunteers. Thromb. Haemost. 1995; 73: 398-401.</mixed-citation><mixed-citation xml:lang="en">Eriksson BI, Soderberg K, Widiund L, Wandeii B, Tengborn L. A comparative study of three iow-moiecuiar weight heparins (LMWH) and unfractionated heparin (UH) in healthy voiunteers. Thromb. Haemost. 1995; 73: 398-401.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Moreno Gonzaiez E, Fontcuberta J, De La Liama F. Prophyiaxis of thromboemboiic disease with RO-11 (ROVI), during abdominai surgery. Hepatogastroenterology. 1996; 43: 744-747.</mixed-citation><mixed-citation xml:lang="en">Moreno Gonzaiez E, Fontcuberta J, De La Liama F. Prophyiaxis of thromboemboiic disease with RO-11 (ROVI), during abdominai surgery. Hepatogastroenterology. 1996; 43: 744-747.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kakkar W, Howes J, Sharma V, Kadzioia Z. A comparative, doubie-biind, randomized triai of a new-second generation LMWH (Bemiparin) and UFH in the prevention of post-operative venous thromboemboiism in patients undergoing hip arthropiasty. Thromb. Haemost. 2000; 83: 523-529.</mixed-citation><mixed-citation xml:lang="en">Kakkar W, Howes J, Sharma V, Kadzioia Z. A comparative, doubie-biind, randomized triai of a new-second generation LMWH (Bemiparin) and UFH in the prevention of post-operative venous thromboemboiism in patients undergoing hip arthropiasty. Thromb. Haemost. 2000; 83: 523-529.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Abad JI, Gomez-Outes A, Martinez-Gonzaiez J, Rocha E. A prospective observationai study on the effectiveness and safety of be-miparin, first dose administered 6 h after knee or hip repiacement surgery. Arch Orthop Trauma Surg. 2007 Oct; 127 (8): 665-670.</mixed-citation><mixed-citation xml:lang="en">Abad JI, Gomez-Outes A, Martinez-Gonzaiez J, Rocha E. A prospective observationai study on the effectiveness and safety of be-miparin, first dose administered 6 h after knee or hip repiacement surgery. Arch Orthop Trauma Surg. 2007 Oct; 127 (8): 665-670.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Navarro-Quiiis A, Casteiiet E, Rocha E, Paz-Jimenez J, Pianes A. Efficacy and safety of bemiparin compared with Enoxaparin in the prevention of venous thromboemboiism after totai knee arthropiasty. A randomized doubie-biind ciinicai triai. J. Thromb. Haemost. 2003; 1: 425-432.</mixed-citation><mixed-citation xml:lang="en">Navarro-Quiiis A, Casteiiet E, Rocha E, Paz-Jimenez J, Pianes A. Efficacy and safety of bemiparin compared with Enoxaparin in the prevention of venous thromboemboiism after totai knee arthropiasty. A randomized doubie-biind ciinicai triai. J. Thromb. Haemost. 2003; 1: 425-432.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Vavken P, Lunzer A., Grohs JG. A prospective cohort study on the effectiveness of 3500 IU versus 5000 IU bemiparin in the prophyiaxis of postoperative thrombotic events in obese patients undergoing orthopedic surgery. Wien Klin Wochenschr. 2009; 121 (13-14): 454-458.</mixed-citation><mixed-citation xml:lang="en">Vavken P, Lunzer A., Grohs JG. A prospective cohort study on the effectiveness of 3500 IU versus 5000 IU bemiparin in the prophyiaxis of postoperative thrombotic events in obese patients undergoing orthopedic surgery. Wien Klin Wochenschr. 2009; 121 (13-14): 454-458.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Rodriguez-Manas L, Gomez-Hueigas R, Veiga-Fernandez F, Ruiz GM, Gonzaiez JM Thromboprophyiaxis with the iow-moiecuiar-weight heparin bemiparin sodium in eid-eriy medicai patients in usuai ciinicai practice: the ANCIANOS study. Clin Drug Investig. 2010; 30 (5): 337-345.</mixed-citation><mixed-citation xml:lang="en">Rodriguez-Manas L, Gomez-Hueigas R, Veiga-Fernandez F, Ruiz GM, Gonzaiez JM Thromboprophyiaxis with the iow-moiecuiar-weight heparin bemiparin sodium in eid-eriy medicai patients in usuai ciinicai practice: the ANCIANOS study. Clin Drug Investig. 2010; 30 (5): 337-345.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Baiibrea JL, Aitimiras J, Larruzea I, Gomez-Outes A, Martinez-Gonzaiez J, Rocha E. Optimai dosing of bemiparin as prophyiaxis against venous thromboemboiism in surgery for cancer: an audit of practice. Int J Surg. 2007 Apr; 5 (2): 114-119.</mixed-citation><mixed-citation xml:lang="en">Baiibrea JL, Aitimiras J, Larruzea I, Gomez-Outes A, Martinez-Gonzaiez J, Rocha E. Optimai dosing of bemiparin as prophyiaxis against venous thromboemboiism in surgery for cancer: an audit of practice. Int J Surg. 2007 Apr; 5 (2): 114-119.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kakkar W, Baiibrea JL, Martinez-Gonzaiez J, Prandoni P. Extended prophyiaxis with bemiparin for the prevention of venous thromboemboiism after abdominai or peivic surgery for cancer: the CANBE-SURE randomized study. J Thromb Haemost. 2010 Jun; 8 (6): 1223-1229.</mixed-citation><mixed-citation xml:lang="en">Kakkar W, Baiibrea JL, Martinez-Gonzaiez J, Prandoni P. Extended prophyiaxis with bemiparin for the prevention of venous thromboemboiism after abdominai or peivic surgery for cancer: the CANBE-SURE randomized study. J Thromb Haemost. 2010 Jun; 8 (6): 1223-1229.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kakkar W, Gebska M, Kadzioia Z, Saba N, Carrasco P. Lowmoiecuiar weight heparin in the acute and iong-term treatment of deep- vein-thrombosis. Thromb. Haemost. 2003; 89: 674-680.</mixed-citation><mixed-citation xml:lang="en">Kakkar W, Gebska M, Kadzioia Z, Saba N, Carrasco P. Lowmoiecuiar weight heparin in the acute and iong-term treatment of deep- vein-thrombosis. Thromb. Haemost. 2003; 89: 674-680.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Santamaria A, Juarez S, Reche A, Gomez-Outes A, Martinez-Gonzaiez J, Fontcuberta J. Low-moiecuiar-weight heparin, bemiparin, in the outpatient treatment and secondary prophyiaxis of venous thromboemboiism in standard ciinicai practice: the ESFERA study. Int J Clin Pract. 2006; 60 (5): 518-525.</mixed-citation><mixed-citation xml:lang="en">Santamaria A, Juarez S, Reche A, Gomez-Outes A, Martinez-Gonzaiez J, Fontcuberta J. Low-moiecuiar-weight heparin, bemiparin, in the outpatient treatment and secondary prophyiaxis of venous thromboemboiism in standard ciinicai practice: the ESFERA study. Int J Clin Pract. 2006; 60 (5): 518-525.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Lecumberri R, Rosario E, Pacho J, Rocha E. Fixed-dose iow- moiecuiar-weight heparin, bemiparin, in the iong-term treatment of venous thromboemboiism in patients with transient risk factors in standard ciinicai practice: the FLEBUS study. J Thromb Haemost. 2006; 4: 2504-2508.</mixed-citation><mixed-citation xml:lang="en">Lecumberri R, Rosario E, Pacho J, Rocha E. Fixed-dose iow- moiecuiar-weight heparin, bemiparin, in the iong-term treatment of venous thromboemboiism in patients with transient risk factors in standard ciinicai practice: the FLEBUS study. J Thromb Haemost. 2006; 4: 2504-2508.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Constans M, Santamaria A, Mateo J, Pujoi N, Souto JC, Font-cuberta J. Low-moiecuiar-weight heparin as bridging therapy during interruption of orai anticoaguiation in patients undergoing coionoscopy or gastroscopy. Int J Clin Pract. 2007; 61: 212-217.</mixed-citation><mixed-citation xml:lang="en">Constans M, Santamaria A, Mateo J, Pujoi N, Souto JC, Font-cuberta J. Low-moiecuiar-weight heparin as bridging therapy during interruption of orai anticoaguiation in patients undergoing coionoscopy or gastroscopy. Int J Clin Pract. 2007; 61: 212-217.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Aiaiaf SK, Jawad RK, Muhammad PR, Aii MS, Ai Tawii NG. Bemiparin versus enoxaparin as thromboprophyiaxis foiiowing vaginai and abdominai deiiveries: a prospective ciinicai triai. BMCPregnancy Childbirth. 2015 Mar 28; 15: 72.</mixed-citation><mixed-citation xml:lang="en">Aiaiaf SK, Jawad RK, Muhammad PR, Aii MS, Ai Tawii NG. Bemiparin versus enoxaparin as thromboprophyiaxis foiiowing vaginai and abdominai deiiveries: a prospective ciinicai triai. BMCPregnancy Childbirth. 2015 Mar 28; 15: 72.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Ciccone MM, Cortese F, Corbo F, Corraies NE, Ai-Momen AK, Siiva A, Zito A, Pinto M, Gesuaido M, Scicchitano P. Bemiparin, an effective and safe iow moiecuiar weight heparin: a review. Vascul Pharmacol. 2014 Jui; 62(1): 32-7.</mixed-citation><mixed-citation xml:lang="en">Ciccone MM, Cortese F, Corbo F, Corraies NE, Ai-Momen AK, Siiva A, Zito A, Pinto M, Gesuaido M, Scicchitano P. Bemiparin, an effective and safe iow moiecuiar weight heparin: a review. Vascul Pharmacol. 2014 Jui; 62(1): 32-7.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
